Rules-Based Medicine | GenomeWeb

Rules-Based Medicine

A consortium of researchers working as part of the Alzheimer's Disease Neuroimaging Initiative has completed an analysis of potential plasma protein biomarkers for Alzheimer's in three separate patient cohorts, identifying four analytes associated with the disease.

After reporting a 27 percent increase in its fiscal third quarter revenues, Myriad Genetics this week outlined three strategic directives for diversifying its revenue base, including growing sales of its existing tests in the US, launching new tests and companion diagnostics in a

By Turna Ray
Myriad Genetics' recent investments to bolster the visibility of its molecular diagnostics products beyond its flagship BRACAnalysis test appear to be paying off.

By Adam Bonislawski
A Stanford University-led research team has identified plasma proteins linked to declines in neurogenesis and impaired learning and memory.

Myriad Genetics reported companion diagnostics revenues of $2 million for its fiscal fourth-quarter compared to none the year before, a result of its $80 million purchase this spring of protein biomarker firm Rules-Based Medicine (

The figure comes from a report commissioned by proteomics firm Proteome Sciences, which, like a number of other protein biomarker firms including Quanterix, Rules-Based Medicine, and NextGen Sciences, has made AD a significant focus of its R&D and commercialization efforts.

The company used its DiscoveryMAP quantitative immunoassay platform to identify a promising multi-protein biomarker pattern using blood samples provided by Roche from a late-stage drug trial.


Harvard's George Church discusses HGP-write with the Journal of the American Medical Association.

In Nature this week: genetic history of HIV in the US, and more.

There are a few projects aimed at addressing the lack of diversity in genomic research, Technology Review reports.

A national assessment shows that US students lag in the sciences, but suggests that achievement gaps are narrowing.